Daniel Chapman

Daniel Chapman is a Senior Research Associate in Assay Development based in the Wolfson Laboratory within the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Oxford Population Health.

He has led immunoassay development, biomarker stability studies and pre-analytical validation, contributing to major randomised trials and population studies including EASi-KIDNEY, REVEAL, STICS, EMPA-Kidney, HARP-3 (UK) and the China Kadoorie Biobank.

His research focuses on the development of high-throughput quantitative and multiplex biomarker assays across multiple analytical platforms, including plate-based immunoassay and targeted mass spectrometry. To support this, he develops liquid handling automation workflows and laboratory informatics systems to improve the robustness, scalability and traceability of biomarker measurement. His work includes the structured application of AI-assisted tools.

He has a particular interest in translating proteomic findings into quantitative assays suitable for large clinical trials and epidemiological studies.

Prior to joining CTSU, Daniel completed a PhD in Clinical Biochemistry and Clinical Research at the University of Exeter.